

Citius Pharmaceuticals, Inc. is a diversified late-stage biopharmaceutical company with multiple near-term catalysts:

- FDA decision on BLA submission for rare cancer drug anticipated August 13, 2024
- 2024 commercialization of first product, LYMPHIR, planned if approved
- Publication of positive Phase 3 trial results for novel antibiotic lock solution designed to salvage catheters in patients with catheter-related blood stream infections expected
- Spin-off of oncology subsidiary to form separate publicly listed company underway

DIVERSIFIED PIPELINE

MINO-LOK®

A novel first and only antibiotic lock solution to salvage central venous catheters (CVCs) in patients with catheter-related bloodstream infections.

- **Status:** Positive Topline results with full data analysis underway; engaging with FDA next steps in Mino-Lok program; eligible for FDA priority review of NDA once submitted.
- **Positive Phase 3 Topline results:** Achieved primary and secondary endpoints; Mino-Lok outperforms hospital-specific anti-infective lock solutions.
- **Market:** Catheter-related bloodstream infection (CRBSI) and central line-associated bloodstream infection (CLABSI) market total estimated at >\$1.8B worldwide.
- **First and only advantage:** No current FDA-approved or investigational products for salvaging infected CVCs; potential to change standard of care.

LYMPHIR™

The only systemic therapy to work on the IL-2 receptor in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), both as a targeted therapy that eliminates malignant T cells in the skin and as an immunotherapy that depletes Tregs.

- **Status:** Prescription Drug User Fee Act (PDUFA) target action date August 13, 2024; 2H 2024 commercialization planned, if approved.
- **Positive Phase 3 results:** 36% objective response rate in heavily pretreated (median of 4 prior therapies; significant reduction in skin tumors for 84% of patients).
- **Market:** Estimated \$300-\$400+M addressable U.S. market with additional growth opportunities; historically, new market entrants have expanded the size of the market.
- **Market advantage:** No curative therapeutics on the market. Only IL-2R targeted therapy.

HALO-LIDO

A proprietary topical cream formulation intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids.

- **Status:** Dose for Phase 3 trial selected; ongoing engagement with FDA.
- **Positive Phase 2b results:** Meaningful reduction in symptom severity when compared to individual components alone.
- **Market:** +10M patients report symptoms of hemorrhoidal disease; 1/3 seek physician treatment.¹
- **First and only advantage:** No FDA-approved prescription hemorrhoid products available.

INVESTMENT HIGHLIGHTS

- **Strong Momentum in 2024.** Three potentially transformative near-term catalysts for late-stage assets.
- **Diversified Portfolio of Potential First-in-Class Products.** Critical care treatments for three large and underserved health concerns; unique commercial advantages.
- **Attractive Multi-Billion Dollar Global Market Opportunities.** Adjunctive cancer care, infectious disease, and gastrointestinal disease.
- **Proven Leadership Team.** Extensive pharma operational and value creation track record pre-Citius.
- **Strong Financial Platform.** Financial stewardship supports pipeline development and investment in long-term growth; \$26.5 M invested by insiders.

BUSINESS DEVELOPMENT

CITIUS ONCOLOGY

Merger of wholly owned subsidiary with TenX Keane Acquisition (Nasdaq: TENK) to form publicly listed Citius Oncology.

- Transaction progressing, pending review by Securities and Exchange Commission (SEC) and TENK shareholder approval.
- Intended to unlock value of the Company's oncology business, which management believes is not currently priced into valuation.
- Facilitates greater access to capital markets for Citius Oncology.
- Citius to receive \$675M in shares of Citius Oncology and retain ~90% equity.

ADDITIONAL LYMPHIR™ OPPORTUNITIES

LYMPHIR's differentiated mechanism-of-action may offer potential beyond CTCL. Two Investigator-initiated Phase 1 studies are underway:

- LYMPHIR in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) at the University of Pittsburgh.
- LYMPHIR given prior to lymphodepletion chemotherapy and FDA-approved CAR-Ts² for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma, who are at a high risk of failure of CAR-T therapy alone at the University of Minnesota.

CITIUS OFFICERS



Leonard Mazur

CHAIRMAN & CEO,
CO-FOUNDER



Myron Holubiak

EXECUTIVE VICE CHAIRMAN,
CO-FOUNDER



Jamie Bartushak

CFO & CHIEF BUSINESS
OFFICER, EVP



Myron Czuczman, MD

CHIEF MEDICAL OFFICER,
EVP



STOCK DATA

Share Price	52-Wk. Range	Avg. Vol.	Shares O/S	Market Cap
\$0.64 (6/12/24)	\$0.60 - \$1.40	1.5M	180.6M	\$116.7M

¹MAYO CLINIC Hemorrhoidal disease: Diagnosis and management

²KYMRIAH, YESCARTA, and BREYANZI

Citius Pharmaceuticals, Inc.

11 Commerce Drive, First Floor
Cranford, NJ 07016
www.citiuspharma.com



Investor Relations Contact

Ilanit Allen
(908) 967-6677 x113
ir@citiuspharma.com

Forward-Looking Statements: This fact sheet has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this document is, or should be construed as, a recommendation, promise or representation by the Company or any director, employee, agent, or adviser of the Company. This document does not purport to be all-inclusive or to contain all of the information you may desire. The Company assumes no obligation to update any statement after the date of this document as a result of new information, subsequent events or any other circumstances. This document includes express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of the Company that are not historical facts. Such forward-looking statements may be identified by words such as "believes", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. The accuracy of such statements is dependent upon future events, and involves known and unknown risks, uncertainties and other factors beyond the Company's control that may cause actual results to differ materially from what is presented herein. Investors are strongly encouraged to carefully review the Company's SEC filings for a listing of the risks that could cause actual results to differ from these forward-looking statements. Information provided in this document speaks only as of the date hereof and should not be construed as statements of facts.